N,N'-bis-(2-amino-ethyl)-2-[6-(tetrahydro-pyran-2-yloxy)-hexyl]-malonamide | 874196-45-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: N,N'-bis-(2-amino-ethyl)-2-[6-(tetrahydro-pyran-2-yloxy)-hexyl]-malonamide
• 英文别名: N,N'-Bis(2-aminoethyl)-2-[6-(tetrahydro-pyran-2-yloxy)-hexyl]-malonamide；N,N'-bis(2-aminoethyl)-2-[6-(oxan-2-yloxy)hexyl]propanediamide
• CAS: 874196-45-9
• 化学式: C₁₈H₃₆N₄O₄
• 分子量: 372.508
• InChiKey: CLOYJKNPKGLZSK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  26
• 可旋转键数：
  14
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  129
• 氢给体数：
  4
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  N,N'-bis-(2-amino-ethyl)-2-[6-(tetrahydro-pyran-2-yloxy)-hexyl]-malonamide 在 对甲苯磺酸 、 氨 作用下， 以 乙醇 、 水 为溶剂， 反应 16.0h， 以69%的产率得到N,N'-bis(2-aminoethyl)-2-(6-hydroxy-hexyl)-malonamide
  参考文献：
  名称：

  WO2007/138291

  摘要：

  公开号：
• 作为产物：
  描述：

  6-氯-1-己醇 在 对甲苯磺酸 sodium 作用下， 以 乙醚 、 乙醇 为溶剂， 反应 57.5h， 生成 N,N'-bis-(2-amino-ethyl)-2-[6-(tetrahydro-pyran-2-yloxy)-hexyl]-malonamide
  参考文献：
  名称：

  WO2007/138291

  摘要：

  公开号：

文献信息

• Novel Imaging Agents for Fibrosis
  申请人：Chettibi Salah

  公开号：US20080279765A1

  公开（公告）日：2008-11-13

  The present invention provides a novel imaging agent targeting the mannose-6-phosphate (M6P) receptor suitable for the non-invasive visualization of fibrosis. A method for the preparation of the imaging agent is also provided by the invention, as well as a precursor for use in said method. The invention also provides a pharmaceutical composition comprising the imaging agent and a kit for the preparation of the pharmaceutical composition. In a further aspect, use of the imaging agent for in vivo imaging and in the preparation of a medicament for the diagnosis of a condition in which the mannose-6-phosphate receptor is upregulated is provided.

  本发明提供了一种新型的成像剂，针对甘露糖-6-磷酸（M6P）受体，适用于非侵入性可视化纤维化。本发明还提供了一种用于制备成像剂的方法，以及用于该方法的前体。本发明还提供了包括成像剂的药物组合物以及用于制备药物组合物的工具包。在另一个方面，本发明提供了利用成像剂进行体内成像和制备用于诊断甘露糖-6-磷酸受体上调病况的药物的方法。
• N4 Chelator Conjugates
  申请人：Storey Anthony Eamonn

  公开号：US20080131368A1

  公开（公告）日：2008-06-05

  The present invention provides tetra-amine chelator conjugates with biological targeting moieties, linked via a linker group and technetium complexes thereof as radiopharmaceuticals. The linker group is such that the chelator is mono-functionalised at the bridgehead position and provides both flexibility and a lack or aryl groups, to minimise lipophilicity and steric hulk. Protected versions of the chelators are provided which permit conjugation with a wide range of targeting molecules without interfering reactions with the amine nitrogens of the tetra-amine chelator. Syntheses of the functionalised chelators are described, together with bifunctional chelate precursors. Radiopharmaceutical compositions comprising the technetium metal complexes of the invention are described, together with non-radioactive kits for the preparation of such radiopharmaceuticals.

  本发明提供了四胺螯合物共轭体，其具有生物靶向基团，通过连接基团和银的技术复合物作为放射性药物。连接基团使得螯合物在桥头位置上单功能化，并提供了灵活性和缺乏芳基团，以最小化亲脂性和立体障碍。本发明提供了保护型螯合物，允许与广泛的靶向分子结合，而不会干扰四胺螯合物的胺氮原子的反应。本发明还描述了功能化螯合物的合成，以及双功能螯合前体。本发明还描述了包括本发明技术复合物的放射性药物组合物，以及用于制备这种放射性药物的非放射性试剂盒。
• N4 chelator conjugates
  申请人：GE Healthcare Limited

  公开号：US07767796B2

  公开（公告）日：2010-08-03

  The present invention provides tetra-amine chelator conjugates with biological targeting moieties, linked via a linker group and technetium complexes thereof as radiopharmaceuticals. The linker group is such that the chelator is mono-functionalized at the bridgehead position and provides both flexibility and a lack or aryl groups, to minimize lipophilicity and steric hulk. Protected versions of the chelators are provided which permit conjugation with a wide range of targeting molecules without interfering reactions with the amine nitrogens of the tetra-amine chelator. Syntheses of the functionalised chelators are described, together with bifunctional chelate precursors. Radiopharmaceutical compositions comprising the technetium metal complexes of the invention are described, together with non-radioactive kits for the preparation of such radiopharmaceuticals.

  本发明提供了具有生物靶向物质的四胺螯合物共轭物，通过连接基团和铝的技术复合物作为放射性药物。连接基团是这样的，即螯合物在桥头位置上是单功能化的，并提供了灵活性和缺乏芳基团，以最小化亲脂性和立体障碍。提供了受保护的螯合物版本，允许与广泛的靶向分子结合，而不会干扰四胺螯合物的胺基氮的反应。描述了功能化螯合物的合成，以及双功能螯合前体。描述了本发明的铝金属复合物的放射性药物组成，以及用于制备这种放射性药物的非放射性试剂盒。
• Imaging agents
  申请人：GE Healthcare Limited

  公开号：US08304388B2

  公开（公告）日：2012-11-06

  The present invention provides a novel imaging agent suitable for the non-invasive visualization of fibrosis. A precursor for the preparation of the imaging agent is also provided by the invention, as well as a pharmaceutical composition comprising the imaging agent and a kit for the preparation of the pharmaceutical composition. In a further aspect, use of the imaging agent for in vivo imaging and in the preparation of a medicament for the diagnosis of a condition which comprises fibrosis is provided.

  本发明提供了一种新型的成像剂，适用于非侵入性可视化纤维化。发明还提供了成像剂的制备前体，以及包含成像剂的药物组合物和制备药物组合物的工具包。在另一个方面，本发明提供了成像剂在体内成像和制备诊断包含纤维化病症的药物的用途。
• NOVEL IMAGING AGENTS
  申请人：Chettibi Salah

  公开号：US20090191123A1

  公开（公告）日：2009-07-30

  The present invention provides a novel imaging agent suitable for the non-invasive visualization of fibrosis. A precursor for the preparation of the imaging agent is also provided by the invention, as well as a pharmaceutical composition comprising the imaging agent and a kit for the preparation of the pharmaceutical composition. In a further aspect, use of the imaging agent for in vivo imaging and in the preparation of a medicament for the diagnosis of a condition which comprises fibrosis is provided.

  本发明提供了一种新颖的成像剂，适用于非侵入性可视化纤维化。本发明还提供了一种用于制备成像剂的前体，以及包含成像剂的药物组合物和制备药物组合物的套件。在进一步的方面，本发明提供了成像剂的使用，用于体内成像和制备用于诊断包括纤维化的病症的药物。